Verona Pharma PLC Holding(s) in Company - Replacement (0344G)
August 02 2016 - 11:26AM
UK Regulatory
TIDMVRP
RNS Number : 0344G
Verona Pharma PLC
02 August 2016
The following announcement replaces the notification Ref 9994F
issued on 2 August 2016. The amendment is to Section 9 which should
read as follows: The voting rights are managed and controlled by
Edmond de Rothschild Investment Partners, acting in its capacity of
management company of BioDiscovery 4 FPCI (not BioDiscovery 5
FPCI). All other details remain unchanged. The full amended text is
shown below.
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i)
--------------------------------------------------
1. Identity of the issuer or Verona Pharma plc
the underlying issuer
of existing shares to which
voting rights are
attached: (ii)
----------------------------------------------------------- ---------------------
2 Reason for the notification (please tick the appropriate
box or boxes):
----------------------------------------------------------------------------------
An acquisition or disposal of voting rights x
------------------------------------------------------------ --------------------
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached
------------------------------------------------------------ --------------------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
------------------------------------------------------------ --------------------
An event changing the breakdown of voting rights
------------------------------------------------------------ --------------------
Other (please
specify):
---------------------------------------------------------- --------------------
3. Full name of person(s) BioDiscovery 4 FPCI
subject to the
notification obligation:
(iii)
----------------------------------------------------------- ---------------------
4. Full name of shareholder(s)
(if different from 3.):(iv)
----------------------------------------------------------- ---------------------
5. Date of the transaction 29 July 2016
and date on
which the threshold is
crossed or
reached: (v)
----------------------------------------------------------- ---------------------
6. Date on which issuer 29 July 2016
notified:
----------------------------------------------------------- ---------------------
7. Threshold(s) that is/are
crossed or
reached: (vi, vii) 0% to 4.3%
----------------------------------------------------------- ---------------------
8. Notified details:
----------------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares (viii, ix)
----------------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the
of to the triggering triggering transaction
shares transaction
if
possible
using
the ISIN
CODE
----------- -------------------------------- -----------------------------------------------------------------------
Number Number Number Number of voting % of voting
of of of shares rights rights (x)
Shares Voting
Rights
----------- --------------- --------------- -------------- ---------------------------- -------------------------
Direct Direct Indirect Direct Indirect
(xi) (xii)
----------- ----------- ----------- -------------- -------------- ------------ ------------ -----------
Ordinary
Shares 0 0 110,601,635 110,601,635 4.3%
--------------- --------------- -------------- -------------- ------------ ------------ -----------
B: Qualifying Financial Instruments
----------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------
Type of Expiration Exercise/ Number of voting % of voting
financial date Conversion rights that rights
instrument (xiii) Period (xiv) may be
acquired if
the
instrument
is
exercised/
converted.
--------------- ------------- ------------------------------- ------------------------------ ---------------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments (xv, xvi)
----------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------
Type of Exercise Expiration Exercise/ Number of voting % of voting
financial price date Conversion rights instrument rights (xix,
instrument (xvii) period refers to xx)
(xviii)
------------- ------------- ------------- ---------------- ------------------------------ -----------------------
Nominal Delta
------------- ------------- ------------- ---------------- ------------------------------ ------------ ---------
Total (A+B+C)
----------------------------------------------------------------------------------------------------------------------
Number of voting rights Percentage of voting rights
----------------------------------------------- ---------------------------------------------------------------------
110,601,635 4.3%
----------------------------------------------- ---------------------------------------------------------------------
9. Chain of controlled undertakings through which the
voting rights and/or the
financial instruments are effectively held, if applicable:
(xxi)
--------------------------------------------------------------------------------------------
The voting rights are managed and controlled by Edmond
de Rothschild Investment Partners, acting in its capacity
of management company of BioDiscovery 4 FPCI.
Proxy Voting:
--------------------------------------------------------------------------------------------
10. Name of the proxy holder:
------------------------------------------------------------- -----------------------------
11. Number of voting rights proxy
holder will cease
to hold:
------------------------------------------------------------- -----------------------------
12. Date on which proxy holder will
cease to hold
voting rights:
------------------------------------------------------------- -----------------------------
Figures are based on a total
13. Additional information: number of voting rights of
2,565,719,826 as per the
Company's Result of General
Meeting Announcement of 22
July 2016.
------------------------------------------------------------- -----------------------------
14. Contact name: Naveed Siddiqi
Andrei Buzdugan
------------------------------------------------------------- -----------------------------
+33 698 661 203
15. Contact telephone number: +33 140 176 968
------------------------------------------------------------- -----------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLAKBDNQBKDNFK
(END) Dow Jones Newswires
August 02, 2016 11:26 ET (15:26 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024
